Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150396 | 0.80 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1POLBMAPTCYP2C9 | |
| SCHEMBL31361627 | 0.80 | ALDH1A1 (0.47) | ALDH1A1JAK2JAK1POLBMAPT | |
| SCHEMBL16023815 | 0.79 | DRD2 (0.46) | L3MBTL1DRD2ALDH1A1JAK2JAK1 | |
| SCHEMBL19040102 | 0.79 | GAA (0.43) | L3MBTL1ALDH1A1POLBMAPTCYP2C9 | |
| Hydrochloric Acid SCHEMBL17141091 | 0.75 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1POLBMAPTCYP2C9 | |
| SCHEMBL29475931 | 0.72 | MAPT (0.43) | L3MBTL1ALDH1A1POLBMAPTCYP2C9 | |
| SCHEMBL13740907 | 0.72 | ALDH1A1 (0.45) | L3MBTL1ALDH1A1POLBMAPTCYP2C9 | |
| SCHEMBL31361684 | 0.71 | ALDH1A1 (0.47) | ALDH1A1JAK2JAK1POLBMAPT | |
| SCHEMBL16264881 | 0.70 | ALDH1A1 (0.48) | L3MBTL1DRD2ALDH1A1POLBMAPT | |
| SCHEMBL16794506 | 0.70 | GSTP1 (0.46) | ALDH1A1POLBMAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| EP-3126352-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | L3MBTL1 2201/4885DRD2 4779/4885ALDH1A1 3898/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | L3MBTL1 2201/4885DRD2 4779/4885ALDH1A1 3898/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | L3MBTL1 2201/4885DRD2 4779/4885ALDH1A1 3898/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | L3MBTL1 2201/4885DRD2 4779/4885ALDH1A1 3898/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | L3MBTL1 2201/4885DRD2 4779/4885ALDH1A1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.